Bayer Aktiengesellschaft (OTCMKTS:BAYRY) Reaches New 1-Year High – Here’s What Happened

Shares of Bayer Aktiengesellschaft (OTCMKTS:BAYRY) hit a new 52-week high during mid-day trading on Monday . The company traded as high as $11.53 and last traded at $11.51, with a volume of 224844 shares. The stock had previously closed at $11.29.

Wall Street Analysts Forecast Growth

A number of research analysts have issued reports on BAYRY shares. JPMorgan Chase & Co. upgraded Bayer Aktiengesellschaft from a “neutral” rating to an “overweight” rating in a research report on Monday, December 8th. Barclays upgraded shares of Bayer Aktiengesellschaft from an “equal weight” rating to an “overweight” rating in a research report on Tuesday, January 6th. Morgan Stanley upgraded shares of Bayer Aktiengesellschaft from an “equal weight” rating to an “overweight” rating in a report on Wednesday, December 3rd. Finally, Zacks Research downgraded Bayer Aktiengesellschaft from a “strong-buy” rating to a “hold” rating in a research report on Monday, November 3rd. Two research analysts have rated the stock with a Strong Buy rating, four have given a Buy rating and one has assigned a Hold rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Buy”.

Bayer Aktiengesellschaft Stock Up 6.6%

The stock has a fifty day moving average of $9.79 and a 200-day moving average of $8.63. The firm has a market capitalization of $44.56 billion, a price-to-earnings ratio of -134.32, a PEG ratio of 5.60 and a beta of 0.66. The company has a current ratio of 1.14, a quick ratio of 0.71 and a debt-to-equity ratio of 1.10.

About Bayer Aktiengesellschaft

Bayer Aktiengesellschaft is a global life sciences company headquartered in Leverkusen, Germany, with a history dating back to 1863. The company operates across three principal business areas—Pharmaceuticals, Consumer Health and Crop Science—serving customers and markets worldwide. Bayer develops, manufactures and markets prescription medicines, over-the-counter healthcare products and agricultural solutions, and maintains research and development programs focused on new therapies and technologies in its core fields.

In Pharmaceuticals, Bayer focuses on prescription drugs across therapeutic areas such as cardiology, oncology, hematology and women’s health, supporting clinical development and regulatory activities for both marketed products and pipeline candidates.